Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?

Core Insights - Erasca (ERAS) is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, with a market valuation of $3.25 billion [1] Technical Performance - ERAS has experienced a significant surge of 460% over the past year, driven by strong technical momentum [7] - The stock reached a new 3-year high of $10.92 on February 2 and recently traded at $10.74, with a 50-day moving average of $5.34 [8] - Since a "Buy" signal was issued on November 12, shares have increased by 300.12% [2] - The stock has made 13 new highs and is up 194.99% over the past month, with a Relative Strength Index (RSI) of 79.10 [8] Analyst Sentiment - Analyst sentiment is highly speculative, with price targets ranging from $2 to $16, indicating uncertainty about future performance [7] - Despite the bullish technical indicators, ERAS currently has no revenue and is burning cash, making its future dependent on FDA drug approvals [7][8] - Barchart gives ERAS a 100% "Buy" opinion, reflecting strong investor interest [8]